Pulling SEC filings + quote and writing the call…
GH
Guardant Health, Inc.
Next earnings Jul 28, 2026 (after close) · consensus $-0.40 EPS, $324M rev
Last earnings +0.0% on 2026-05-07
$127.26
▼ -3.43%$131.78▲ +167.30%
over 1Y
L $40.98EODHDH $133.22
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today-3.4%
1W+0.7%
1M+34.2%
3M+47.9%
YTD+29.5%
1Y+167.3%
Hold
Conviction
Horizon
Long (>12mo)
Street · 32 analysts
Strong Buy
Fast-growing liquid-biopsy leader with FDA-approved Shield screening, but deep losses, negative equity and a 17.6x sales tag demand patience.
Guardant Health is a leading precision-oncology company whose blood and tissue tests span advanced-cancer profiling (Guardant360), recurrence monitoring (Reveal) and, critically, early detection via Shield — the first FDA-approved and Medicare-covered blood test for primary colorectal cancer screening. The top-line momentum is genuine: FY2025 revenue grew 32.9% to $982M, accelerating off $564M (FY2023) and $739M (FY2024), and the Shield platform has FDA Breakthrough Device designation for a multi-cancer detection test — a large potential market.
Sources: SEC EDGAR (CIK 0001576280, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 8:43:06 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.